Market News & Trends
Opus Genetics Announces FDA Clearance of IND Application for Gene Therapy Candidate
Opus Genetics recently announced the US FDA has accepted its Investigational New Drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1…
Halda Therapeutics Receives FDA Fast Track Designation for Metastatic Castration-Resistant Prostate Cancer Treatment
Halda Therapeutics recently announced the US FDA granted Fast Track designation to HLD-0915, the company’s lead development candidate, for the treatment of patients with metastatic…
Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announced the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients…
Fifty 1 Labs & The Gates Foundation Lead Largest-Ever Sickle Cell Disease Study
Fifty1 AI Labs, Inc. recently announced the completion of the largest and most comprehensive study of Sickle Cell Disease (SCD) ever undertaken. Leveraging a decade's worth…
Superluminal Medicines Announces Collaboration With Eli Lilly to Advance Small Molecule Therapeutics for Cardiometabolic Diseases & Obesity
Superluminal Medicines recently announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and…
Veranova’s Devens Site Successfully Passes FDA Inspection With Zero Observations
Veranova recently announced that a routine current Good Manufacturing Practice (cGMP) surveillance inspection of Veranova’s Devens, Massachusetts site, completed by the Food and Drug Administration…
Colorcon Ventures Invests in Phytolon to Advance the Future of Natural Colorants
Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in Phytolon, a startup company offering natural food coloring via precision fermentation of modified…
BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+ for Cancer
BriaCell Therapeutics Corp. recently announced its acceptance into Memorial Sloan Kettering Cancer Center’s (MSK’s) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the…
MAIA Biotechnology Granted Patent for Next-Generation Telomere-Targeting Agents for Cancer Therapy
MAIA Biotechnology, Inc. recently announced the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer…
NodThera Demonstrates Reversal of Neuroinflammation & Inflammation in Parkinson’s Disease With Oral NLRP3 Inhibitor
NodThera recently announced the full publication of positive data from its Parkinson’s disease Phase 1b/2a study evaluating the effects of NT-0796, its oral, brain-penetrant NLRP3…
AAVantgarde Bio Announces FDA Fast Track Designation for AAVB-039 for the Treatment of Stargardt Disease
AAVantgarde Bio recently announced the US FDA has granted Fast Track Designation for AAVB-039, the company’s gene therapy program for Stargardt disease secondary to biallelic…
Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment for Registrational Trial of AXPAXLI in NPDR
Ocular Therapeutix, Inc. recently announced it has received written agreement regarding a registrational trial design from the US FDA under a Special Protocol Assessment (SPA)…
Enable Injections Announces enFuse System Regulatory Approval & MRHA Medical Device Registration
Enable Injections, Inc. recently announced the Brazilian Health Regulatory Agency (Agencia Nacional de Vigilancia Sanitaria or ANVISA) approved the enFuse system for administration of medication…
Aardvark Therapeutics Announces ARD-201 Preclinical Obesity Data Showing Significant Weight Loss as a Monotherapy, Enhancement of GLP-1RA Therapy in Combination & Effective Maintenance Following Discontinuation of GLP-1RA Therapy
Aardvark Therapeutics, Inc. recently announced new positive preclinical data demonstrating the potential of ARD-201 for the treatment of metabolic obesity and obesity-related conditions. Data in…
Branded Legacy Finalizes Transformative Acquisition of Bio Legacy Evaluative Group, Unlocking Explosive Growth Potential in Biotech & Drug Delivery
Branded Legacy, Inc. recently announced the completion of its game-changing acquisition of Bio Legacy Evaluative Group, formerly Menlo Health (Bio Legacy). This strategic move, executed…
BBOT Debuts as a Publicly Traded Company Focused on RAS-Pathway Malignances With a Potential to Realize the Full Promise of KRAS & PI3K Inhibition
BridgeBio Oncology Therapeutics, Inc. (BBOT) recently announced the closing of its previously announced business combination with Helix Acquisition Corp. II (formerly Nasdaq: HLXB) (Helix), a…
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
XOMA Royalty Corporation recently announced it has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ: TSBX)…
FDA Approves Tiziana Life Sciences' Phase 2 IND for Multiple System Atrophy
Tiziana Life Sciences, Ltd. recently announce the US FDA has approved the IND for its Phase 2a clinical trial of intranasal foralumab in patients with…
Sever Pharma Solutions Expands Partnership With Silo Pharma on Novel Ketamine-Based Implant for Chronic Pain & Fibromyalgia
Sever Pharma Solutions, a leading Contract Development and Manufacturing Organization (CDMO) specializing in controlled-release systems for high potent drugs, recently announced an expanded agreement with…
FoRx Therapeutics Initiates First-in-Human Trial With Novel Anti-Cancer Drug Targeting DNA Damage Response
FoRx Therapeutics recently announced the dosing of the first patient in a first-in-human clinical study of FORX-428, a novel PARG inhibitor designed to target and…
